At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed May 8, 2026 at 06:50 ET
ANI Pharmaceuticals reported Q1 2026 adjusted non-GAAP diluted EPS of $2.05, beating the $1.30 consensus by 57.7%, on revenue of $237.5M (20.5% YoY growth), above the $207.6M consensus. The company raised full-year 2026 guidance for revenue to $1.08B-$1.14B and adjusted EPS to $9.19-$9.69, and authorized a $100M share repurchase program. Cortrophin Gel revenue grew 42.1% YoY to $75.1M, and the Rare Disease segment expanded 36.9%.
- Q1 2026 adjusted non-GAAP diluted EPS of $2.05 vs consensus $1.30 (57.7% beat)
- Q1 2026 total net revenue of $237.5M vs consensus $207.6M (14.4% beat), up 20.5% YoY
- Cortrophin Gel net revenue of $75.1M, up 42.1% YoY
- Raised FY2026 guidance: revenue $1.08B-$1.14B (prev. $1.055B-$1.115B), adjusted EPS $9.19-$9.69 (prev. $8.83-$9.34)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access